Code of Maryland Regulations (Last Updated: April 6, 2021) |
Title 14. Independent Agencies |
Subtitle 04. MARYLAND TECHNOLOGY DEVELOPMENT CORPORATION |
Chapter 14.04.05. Seed Funds |
Sec. 14.04.05.05. Eligibility
-
A. In General. TEDCO shall be satisfied that the applicant meets the requirements under COMAR 14.04.02.04. In addition to the requirements set forth in COMAR 14.04.02.04, TEDCO shall be satisfied that the business is based on the validation of a minimum viable product or, in the case of life sciences, proof of concept data with validation from in vitro or in vivo models or patient samples.
B. Eligibility for Specific Seed Funds.
(1) For Technology Commercialization Fund investments, at the time of the application and initial investment, the business:
(a) Has raised not more than $2,500,000 of dilutive funding, not including the investment; and
(b) Employs not more than 15 employees.
(2) For Cybersecurity Investment Fund investments, the business:
(a) Shall be focused on information technology, including the protection of networked devises, networks, programs, and data from unintended or unauthorized access, change, or destruction; and
(b) At the time of the application and initial investment:
(i) Has raised not more than $2,500,000 of dilutive funding, not including the investment; and
(ii) Employs not more than 15 employees.
(3) For GAP Fund investments, the business:
(a) Shall have secured verifiable funding commitments from non-government sources for a concurrent $1:1 ratio match to TEDCOs investment, the receipt of which by the business shall be a condition of closing the TEDCO investment;
(b) Shall use the proceeds from TEDCOs investment for payroll to compensate new employees in the State hired by the applicant after or not more than 90 days before TEDCOs release of the investment proceeds; and
(c) At the time of application and initial investment:
(i) Has raised not more than $5,000,000 of dilutive funding, not including the investment; and
(ii) Shall employ not more than 30 employees.
(4) For Life Science Investment Fund, the business:
(a) Shall be in the process of developing a technology for a product for human health that requires approval from the United States Food and Drug Administration prior to market; and
(b) At the time of the application and initial investment:
(i) Has raised not more than $2,500,000 of dilutive funding, not including the investment; and
(ii) Employs not more than 15 employees.